Last Updated on January 27, 2021 by The Health Master
Lupin has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.
Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children six years of age and older with chronic kidney disease on dialysis.
Sevelamer Carbonate Tablets (RLD: Renvela) had estimated annual sales of $348 million in the US (IQVIA MAT September 2020).
Also read | Zydus Cadila gets USFDA nod for Thyroid drug
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here